Fate Therapeutics Inc (FATE)

[jondoeuk]

On Monday, Nov 15, they intend to host a virtual investor event, to highlight their emerging pipeline of OTS multiplexed engineered iPSC derived NK and T-cell product candidates for solid tumours.

During the investor event they plan to discuss the following; the multiplexed engineered preclinical candidates for which they intend to submit IND applications during the next 18 months. This includes the unique mechanisms of action that the product candidates seek to exploit and attacking solid tumours, proprietary multiplex engineering and single iPSC selection platform as well as new innovative features and functionality that they are currently assessing for integration into the solid tumour product candidates or multi armed PhI study of FT538 in solid tumours, where they have initiated enrolment in combination with checkpoint inhibitor therapy, in patients with resistance to checkpoint inhibitor and in combination with tumour targeting monoclonal antibody therapy, including those that target the tumour associated antigens, EGFR, HER2 and PD-L1.

Also, they plan to disclose clinical data from our first generation product candidates for solid tumours in patients that have progressed or failed checkpoint inhibitor therapy. The PhI study of FT500 has enrolled approximately 10 patients in dose expansion at 300 million cells per dose, and includes heavily pre-treated patients with non-small cell lung cancer or classical Hodgkin lymphoma that have progressed or failed PD(L)-1 checkpoint inhibitor therapy.

The PhI study of FT516 has enrolled approximately 12 patients in dose escalation, ranging from 90 million cells per dose to 900 million cells per dose, and primarily includes heavily pre-treated patients with Stage IV melanoma that have progressed or failed PD(L)-1 checkpoint inhibitor therapy.